Search | Clinical Trials Finder

Conditions: Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
Interventions: EO2401, Nivolumab; Biological
Lead sponsor: Enterome; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Neuroendocrine Tumor, Metastatic Neuroendocrine Tumor
Interventions: ONC201; Drug
Lead sponsor: Peter Anderson; Other
Eligibility: 14 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma, Male Breast Cancer, Malignant Paraganglioma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pheochromocytoma, Recurrent Prostate Cancer, Recurrent Renal Cell Cancer, Recurrent Small Cell Lung Cancer, Recurrent Uterine Sarcoma, Regional Gastrointestinal Carcinoid Tumor, Regional Pheochromocytoma, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage III Ovarian Epithelial Cancer, Stage III Ovarian Germ Cell Tumor, Stage III Prostate Cancer, Stage III Renal Cell Cancer, Stage III Uterine Sarcoma, Stage IIIA Breast Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Endometrial Carcinoma, Stage IV Neuroendocrine Carcinoma of the Skin, Stage IV Non-small Cell Lung Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Prostate Cancer, Stage IV Renal Cell Cancer, Stage IV Uterine Sarcoma, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Thyroid Gland Medullary Carcinoma
Interventions: temsirolimus, vinorelbine ditartrate; Drug
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Pheochromocytoma
Interventions: [131]I-MIBG, 6-[18F]Fluorodopamine, [123]I-MIBG; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Differentiated Thyroid Gland Carcinoma, Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Thyroid Gland Medullary Carcinoma
Interventions: Computed Tomography, Dual X-ray Absorptiometry, Physical Examination, Quality-of-Life Assessment, Questionnaire Administration, Cabozantinib, Lenvatinib; Procedure · Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pheochromocytoma, Paraganglioma
Interventions: Axitinib (AG-013736); Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Brain and Central Nervous System Tumors, Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neuroblastoma, Pheochromocytoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: 90Y-DOTA-tyr3-OCTREOTIDE; Radiation
Lead sponsor: O'Dorisio, M S; Other
Eligibility: 2 Years to 25 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Locally Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Regional Adrenal Gland Pheochromocytoma, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma
Interventions: Cabozantinib S-malate, Laboratory Biomarker Analysis, Questionnaire Administration; Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid, Unknown Primary Tumors, Neuroendocrine Tumors, Neuroendocrine Skin Carcinoma, Neuroendocrine Breast Tumor, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Neoplasm of Ovary
Interventions: 177Lu-DOTATOC; Drug
Lead sponsor: Excel Diagnostics and Nuclear Oncology Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions: Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P); Diagnostic Test · Drug · Other
Lead sponsor: Taproot Health; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Idaho Falls, Idaho • Laredo, Texas

Conditions: Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma, Meningioma
Interventions: [203Pb]VMT-α-NET, [212Pb]VMT-α-NET; Drug
Lead sponsor: Perspective Therapeutics; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 19
States / cities: Jacksonville, Florida • Miami, Florida • Chicago, Illinois + 16 more

Conditions: Paraganglioma, Pheochromocytoma
Interventions: Lanreotide; Drug
Lead sponsor: Antonio Fojo; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: New York, New York • Cleveland, Ohio

Conditions: Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Unresectable Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma
Interventions: Biospecimen Collection, Computed Tomography with Contrast, Magnetic Resonance Imaging, Olaparib, Quality-of-Life Assessment, Temozolomide; Procedure · Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 163
States / cities: Anchorage, Alaska • Burbank, California • Fort Lauderdale, Florida + 120 more

Conditions: Pheochromocytoma, Paraganglioma
Interventions: Axitinib; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma
Interventions: Laboratory Biomarker Analysis, Lenvatinib, Quality-of-Life Assessment; Other · Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Neuroblastoma, Pheochromocytoma
Interventions: iobenguane I 131; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 1 Year and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma, Paragangliomas
Interventions: 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2039
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma, Esthesioneuroblastoma, Olfactory Neuroblastoma, Somatostatin Receptor Positive, Small Cell Lung Cancers, Pheochromocytoma/Paragangliomas, Kidney Cancers, Head and Neck Tumors, Gastrointestinal Neuroendocrine Tumors
Interventions: 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor, Metastatic Pheochromocytoma, Pancreatic Polypeptide Tumor, Recurrent Gastrointestinal Carcinoid Tumor, Recurrent Islet Cell Carcinoma, Recurrent Melanoma, Recurrent Neuroendocrine Carcinoma of the Skin, Recurrent Non-small Cell Lung Cancer, Recurrent Pheochromocytoma, Recurrent Renal Cell Cancer, Somatostatinoma, Stage III Neuroendocrine Carcinoma of the Skin, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer, Stage IV Renal Cell Cancer, Thyroid Gland Medullary Carcinoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: everolimus, vatalanib, pharmacological study, laboratory biomarker analysis, dynamic contrast-enhanced magnetic resonance imaging, ultrasound imaging; Drug · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2018
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Extra-Adrenal Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Paraganglioma, Recurrent Adrenal Gland Pheochromocytoma
Interventions: Laboratory Biomarker Analysis, Pazopanib Hydrochloride; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 9
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Baltimore, Maryland + 6 more

Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Recurrent Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Uveal Melanoma, Acral Melanoma, Neuroendocrine Tumors, Paraganglioma, Pheochromocytoma, Adrenocortical Carcinoma, Pancreatic Neuroendocrine Tumor, Thyroid Cancer, Breast Cancer, Lung Adenocarcinoma, Head and Neck Squamous Cell Carcinoma
Interventions: Biopsy, Biospecimen Collection, Computed Tomography, Cyclophosphamide, Fludarabine Phosphate, Fludeoxyglucose F-18, IL13Ralpha2-specific Hinge-optimized 4-1BB-co-stimulatory CAR/Truncated CD19-expressing Autologous TN/MEM Cells, Magnetic Resonance Imaging, Positron Emission Tomography; Procedure · Drug · Other + 1 more
Lead sponsor: Anusha Kalbasi; Other
Eligibility: 18 Years to 75 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Duarte, California • Los Angeles, California • Stanford, California

Conditions: Pheochromocytoma, Paraganglioma
Interventions: 131I-MIBG; Radiation
Lead sponsor: University of California, San Francisco; Other
Eligibility: 4 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1991 – 2009
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Neuroendocrine Tumors
Interventions: Capecitabine, Temozolomide; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Adrenocortical Carcinoma, Pheochromocytoma, Paraganglioma
Interventions: Ivonescimab; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma

Phase 2 Study of ONC201 in Neuroendocrine Tumors

Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors

131MIBG to Treat Malignant Pheochromocytoma

Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine Cancer

Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

The Registry of Oncology Outcomes Associated With Testing and Treatment

Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors

LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA)

Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer

Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma

Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy

[212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

Capecitabine and Temozolomide for Neuroendocrine Cancers

STOMP OUT: A Phase 2 Study To Evaluate The Effects Of Ivonescimab In Patients With Unresectable/Metastatic Adrenocortical Carcinoma (ACC) Or Unresectable Pheochromocytoma/Paraganglioma (PPGL)